National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 1) (PB 9 of 2017) (Cth)

PB 9 of 2017

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 1)

National Health Act 1953

I, KAREN BINNEKAMP, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated      20 January 2017

KAREN BINNEKAMP

Assistant Secretary (Acting)

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 1).

(2)   This Determination may also be cited as PB 9 of 2017.

1. Commencement

This Determination commences on 1 February 2017.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Cefuroxime

Insert

Ceritinib

[2]     Schedule 1, after item dealing with Ivermectin

Insert

Ixekizumab

[3]     Schedule 1, after item dealing with Ofloxacin

Insert

Olaparib

[4]     Schedule 1, after item dealing with Silver sulfadiazine

Omit

Simeprevir

[5]   Schedule 2, after item dealing with Cabazitaxel

Insert

Calcipotriol with betamethasone